DESCRIPTION (provided by applicant): Muscle wasting is a prevalent health care problem that has a high morbidity in the adult population and causes a loss of muscle strength, increased vulnerability to falls, increased health care utilization and a reduced quality of life. In order to develop novel therapies that will achieve optimal reversal of muscle wasting, it is important to understand cellular and molecular changes to the muscle fiber during both catabolic and anabolic processes. Testosterone (and presumably selective androgen receptor modulators or SARMs) has been shown to induce satellite cell activation as a first step in muscle fiber hypertrophy/new fiber formation, but the mechanism is unknown. A more complete understanding of satellite cell activation would be a significant contribution towards our long term goal of developing novel strategies for reversal of muscle wasting. The goals of the proposed studies are: (1) to compare and contrast the cellular and molecular effects of androgen deprivation and subsequent testosterone or SARM supplementation on muscles with varying responsiveness to androgens; and (2) to examine the hypothesized role of androgens in mediating satellite cell activation through a NOS/HGF pathway. Methods include muscle fiber assays to evaluate the changes in myonuclear number and protein synthesis; protein assays of specific factors involved in satellite cell activation; and molecular assays to determine changes in RNA message for expression of factors related to androgens and satellite cell activation. Understanding the signaling and subsequent activation of muscle satellite cells by androgen is an important milestone towards the predictable management of muscle wasting conditions. Pathways leading to satellite cell activation are likely to be complex and may vary according to a particular stimulus. The significance of the proposed research will be to explore a known stimulus, androgen, and identify a pathway that can be valuable for the development of novel therapeutic interventions. Muscle wasting is a widespread health care problem causing a loss of muscle strength, increased chance of falls, increased health care use and a reduced quality of life. Testosterone treatment reverses muscle wasting but has many side effects. In order to develop new treatments that will reverse muscle wasting, it is important to understand cellular and molecular changes to the muscle fiber during both wasting and hypertrophy. The proposed research will explore a known stimulus, testosterone or testosterone-like compound (SARM), to identify the pathway of action and allow for the development of new treatments for muscle wasting.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AdultAdverse effectsAgingAndrogen ReceptorAndrogensAnimalsAnteriorBindingBiological AssayBiological AvailabilityCastrationChronic Obstructive Airway DiseaseComplexConditionDataDevelopmentDiseaseExposure toFiberFlutamideGoalsGrowth FactorHIVHealthcareHepaticHormonesHypertrophyKidneyLimb structureMalignant neoplasm of prostateMasseter MuscleMediatingMethodsModelingMolecularMorbidity - disease rateMuscleMuscle FibersMuscle satellite cellMuscular DystrophiesMyosin Heavy ChainsNG-Nitroarginine Methyl EsterNitric OxideNitric Oxide SynthaseNumbersOralPathway interactionsPersonal SatisfactionPhenotypePopulationProcessProductionProstateProtein BiosynthesisProteinsQuality of lifeRNARecoveryResearchRiskRoleSeminal VesiclesSignal TransductionSkeletal MuscleSpeedStimulusStretchingSupplementationTestingTestosteroneTherapeutic InterventionTissuesbasebonecross reactivitydeprivationfallshealth care service utilizationin vitro Modelin vivolevator ani musclemalemuscle hypertrophymuscle strengthneutralizing antibodynovelnovel strategiesnovel therapeuticsnumb proteinreceptorreceptor bindingresponsesarcopeniasatellite cellselective androgen receptor modulatorsizewasting
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
969663814
UEI
NNFQH1JAPEP3
Project Start Date
01-September-2007
Project End Date
31-August-2009
Budget Start Date
01-September-2007
Budget End Date
31-August-2008
Project Funding Information for 2007
Total Funding
$219,750
Direct Costs
$150,000
Indirect Costs
$69,750
Year
Funding IC
FY Total Cost by IC
2007
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$219,750
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21HD055286-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21HD055286-01
Patents
No Patents information available for 1R21HD055286-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21HD055286-01
Clinical Studies
No Clinical Studies information available for 1R21HD055286-01
News and More
Related News Releases
No news release information available for 1R21HD055286-01
History
No Historical information available for 1R21HD055286-01
Similar Projects
No Similar Projects information available for 1R21HD055286-01